On February 14, 2014 the U.S. Food and Drug Administration approved a new drug treatment for patients with mucopolysaccharidosis Type IVA, also known as Murquio A Syndrome. The new medication goes by the trade name Vimizim (chemical name elosulfase alfa), and it is marketed in the U.S. by Biomarin, Inc. Murquio A Syndrome is a […]
On February 12, 2014 the U.S. Food and Drug Administration approved a new indication for Imbruvica (chemical name ibrutinib). The drug is now approved to treat patients with chronic lymphocytic leukemia (CLL). Imbruvica was initially approved by the FDA on November 13, 2013 with an indication to treat mantle cell leukemia (MCL), a rare and […]
On December 6, 2013 the U.S. Food and Drug Administration approved a new pill to treat patients with chronic hepatitis C virus (HCV) infection. It is the first antiviral product that has shown safety and efficacy to treat certain types of HCV infection (specifically Genotype 2 and Genotype 3) without the need for concomitant treatment […]
On March 27, 2013 the U.S. Food and Drug Administration announced approval of a new drug to treat multiple sclerosis. The drug, Tecfidera (dimethyl fumarate) is approved for use in adult patients relapsing multiple sclerosis (MS). Tecfidera will be launched in 120 mg and 240 mg delayed release capsule formulations. While the exact mechanism of […]